바이오리액터 시장 기회, 성장 촉진요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Bioreactors Market was valued at USD 13.8 billion in 2025 and is estimated to grow at a CAGR of 11.2% to reach USD 38.9 billion by 2035.

The growth is fueled by the expansion of the pharmaceutical and biotechnology sectors, technological innovations in bioreactor systems, and increasing demand for personalized and advanced therapies. Bioreactors are central to the manufacturing of vaccines, monoclonal antibodies, and cell-based therapies, which are experiencing high demand due to the rising prevalence of chronic diseases and the pursuit of innovative treatment options. Advancements in genetic engineering, regenerative medicine, and biosimilars are driving the need for scalable, efficient, and compliant bioreactor systems capable of supporting large-scale production while maintaining product quality. Investment in single-use systems, automated platforms, and other advanced bioreactor technologies is intensifying as companies focus on biologics and orphan drugs, which are increasingly developed to address rare diseases under supportive regulatory incentives. These factors collectively make bioreactors indispensable in modern biomanufacturing.

The reusable bioreactor segment reached USD 10 billion in 2025. Reusable bioreactors are preferred for large-scale production due to their cost-effectiveness, as they can be sterilized and reused across multiple production cycles. Their durability and versatility allow operations under diverse manufacturing conditions, which is critical for high-yield, complex processes in biopharmaceutical production. These features make reusable systems a cornerstone for efficient biologics manufacturing, where managing large batch volumes without compromising quality is essential.

The mammalian cell segment captured USD 10.3 billion in 2025. Mammalian cells are extensively utilized in producing complex biologics, including monoclonal antibodies, recombinant proteins, and vaccines, because they replicate human cellular behavior, ensuring therapeutic safety and efficacy. These cells are highly sensitive to environmental parameters such as temperature, pH, oxygen concentration, and nutrient availability. Bioreactors provide controlled conditions that optimize cell growth and productivity, making them indispensable in the development of advanced therapies.

U.S. Bioreactors Market was valued at USD 4.7 billion in 2025. The expansion is driven by the country's advanced pharmaceutical and biotechnology sectors, increasing investment in biologics, and rising adoption of personalized medicine. Bioreactors facilitate high-quality, large-scale production of vaccines, monoclonal antibodies, and gene therapies, supporting the U.S. industry's shift toward sophisticated biologics and advanced therapeutic solutions.

Leading players in the Global Bioreactors Market include Danaher Corporation, Thermo Fisher Scientific Inc., Sartorius AG, Merck KGaA, Eppendorf Group, GEA Group Aktiengesellschaft, Altrad Group, Cellexus, CerCell A/S, Donaldson Company, Inc., BaiLun Biotechnology Co., Ltd, Bbi-biotech, Esco Micro Pte. Ltd., and PBS Biotech, Inc. Market participants are focusing on strategies such as expanding global production capacity, integrating automation, and developing next-generation single-use and modular bioreactor systems. Companies are investing in R&D to improve bioreactor efficiency, scalability, and compliance with stringent regulatory standards. Strategic partnerships and acquisitions help strengthen regional presence, secure critical raw material supply chains, and diversify product portfolios. Firms are also leveraging digital technologies, AI-driven process control, and real-time monitoring systems to enhance productivity and operational efficiency.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product type trends
  • 2.2.3 Cell trends
  • 2.2.4 Molecule trends
  • 2.2.5 Usage trends
  • 2.2.6 Material trends
  • 2.2.7 Size trends
  • 2.2.8 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing pharmaceutical and biotechnology industry
    • 3.2.1.2 Technological advancements in bioreactors
    • 3.2.1.3 Growing focus on orphan drug development
    • 3.2.1.4 Rising demand for personalized medicines
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Low capacity of single-use bioreactors
    • 3.2.2.2 Concerns regarding extractables and/or leachables
  • 3.2.3 Market opportunities
    • 3.2.3.1 Precision fermentation for novel healthcare applications
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technological advancements
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Pricing analysis, 2024
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Single-use (Plastic)
• 5.3 Reusable

Chapter 6 Market Estimates and Forecast, By Cell, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Mammalian cells
• 6.3 Bacterial cells
• 6.4 Yeast cells
• 6.5 Other cells

Chapter 7 Market Estimates and Forecast, By Molecule, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Monoclonal antibodies
• 7.3 Vaccines
• 7.4 Recombinant proteins
• 7.5 Stem cells
• 7.6 Gene therapy
• 7.7 Other molecules

Chapter 8 Market Estimates and Forecast, By Usage, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Developmental, pre-clinical & clinical
• 8.3 Commercial production

Chapter 9 Market Estimates and Forecast, By Materials, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Stainless steel
• 9.3 Glass
• 9.4 Single-use

Chapter 10 Market Estimates and Forecast, By Size, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 Less than 500 L
• 10.3 501-5,000 L
• 10.4 More than 5,000 L

Chapter 11 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 11.1 Key trends
• 11.2 R&D organizations
• 11.3 Biopharma manufacturers
• 11.4 Contract manufacturing organizations (CMOs)

Chapter 12 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 12.1 Key trends
• 12.2 North America
  • 12.2.1 U.S.
  • 12.2.2 Canada
• 12.3 Europe
  • 12.3.1 Germany
  • 12.3.2 UK
  • 12.3.3 France
  • 12.3.4 Spain
  • 12.3.5 Italy
  • 12.3.6 Netherlands
• 12.4 Asia Pacific
  • 12.4.1 China
  • 12.4.2 India
  • 12.4.3 Japan
  • 12.4.4 Australia
  • 12.4.5 South Korea
• 12.5 Latin America
  • 12.5.1 Brazil
  • 12.5.2 Mexico
  • 12.5.3 Argentina
• 12.6 Middle East and Africa
  • 12.6.1 Saudi Arabia
  • 12.6.2 South Africa
  • 12.6.3 UAE

Chapter 13 Company Profiles

• 13.1 Altrad Group
• 13.2 BaiLun Biotechnology Co., Ltd
• 13.3 Bbi-biotech
• 13.4 Cellexus
• 13.5 CerCell A/S
• 13.6 Danaher Corporation
• 13.7 Donaldson Company, Inc
• 13.8 Eppendorf Group
• 13.9 Esco Micro Pte. Ltd.
• 13.10 GEA Group Aktiengesellschaft
• 13.11 Getinge AB
• 13.12 Merck KGaA
• 13.13 PBS Biotech, Inc.
• 13.14 Sartorius AG
• 13.15 Thermo Fisher Scientific Inc.